Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S413000, C548S517000, C548S518000, C514S408000, C514S422000
Reexamination Certificate
active
07906550
ABSTRACT:
The present invention relates to compounds of formula I:or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
REFERENCES:
patent: 7241796 (2007-07-01), Farmer et al.
patent: 7273885 (2007-09-01), Pitlik et al.
patent: 7365092 (2008-04-01), Cottrell et al.
Cottrell Kevin M.
Maxwell John
Perni Robert B.
Pitlik Janos
Kelly Susan C.
Shameem Golam M
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2721390